The clinical trial involved 180 adults with obesity who first underwent a 21-week induction phase with weekly subcutaneous injections. During this period, participants achieved weight reductions ranging from 16% to 19%. Following the induction, subjects were randomized into various maintenance schedules to test the drug's efficacy in preventing weight regain. Those transitioned to every-other-week dosing retained 97% of their progress, while those on a monthly regimen maintained up to 90% of their weight loss.
Viking Therapeutics Reports Success in VK2735 Weight Maintenance Trial
Patients treated with Viking Therapeutics' dual GLP-1/GIP agonist VK2735 maintained up to 97% of their initial weight loss after transitioning to less frequent dosing regimens. The study, which spanned 33 weeks, demonstrated that monthly and every-other-week injections offer a viable pathway for sustained weight management without a plateau in results.
Beyond weight control, the maintenance phase showed a strong safety profile. Gastrointestinal side effects, such as nausea and vomiting, remained comparable to those observed in the placebo group, suggesting that the drug is well-tolerated even under flexible administration schedules. Brian Lian, CEO of Viking, noted that these findings provide clinicians with new strategies to help patients transition from initial weight loss to long-term management. The company now intends to evaluate oral maintenance dosing in the next stage of the study to further diversify treatment options.
Comments (0)
No comments yet. Be the first!